Closing Panel Discussion: Future Directions for BCMA-Directed Therapies
Time: 4:00 pm
day: Day Two
- Accessibility changes
- Is improved trial design needed?
- How will they be commercialized?
- What is the ultimate limit of BCMA as a target for myeloma?
- How will cell therapy infrastructure evolve & how will this effect current situation?
- Potential limitations to BCMA and how other targets (FcRb5/FcR115, NC28, CS1, SIRH5) could fit in the future clinical landscape
- Long-term outlook